Journal of Hepatology
Volume 42, Issue 1 , Pages 75-81, January 2005

The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARγ. Influence of albumin

  • Marta López-Parra

      Affiliations

    • DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
  • ,
  • Joan Clària

      Affiliations

    • DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 93 2275400x2814; fax: +34 93 2275454.
  • ,
  • Esther Titos

      Affiliations

    • DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
  • ,
  • Anna Planagumà

      Affiliations

    • DNA Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
  • ,
  • Marcelina Párrizas

      Affiliations

    • Hormonal Laboratory, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
  • ,
  • Jaime L. Masferrer

      Affiliations

    • Pfizer Research and Development, St Louis, MO, USA
  • ,
  • Wladimiro Jiménez

      Affiliations

    • Hormonal Laboratory, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
  • ,
  • Vicente Arroyo

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
  • ,
  • Francisca Rivera

      Affiliations

    • Hormonal Laboratory, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain
  • ,
  • Joan Rodés

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain

Received 11 June 2004; received in revised form 27 August 2004; accepted 21 September 2004. published online 11 October 2004.

Background/Aims

Selective cyclooxygenase (COX)-2 inhibitors do not adversely affect renal function in experimental cirrhosis. In the current study, we investigated the molecular mechanisms underlying the effects of the selective COX-2 inhibitor, celecoxib, and assessed the influence of albumin on its actions.

Methods

Rat mesangial cells (RMC) were incubated with celecoxib in the absence or presence of albumin, and levels of selected vasoconstrictor eicosanoids, renin release and α-smooth muscle actin (α-SMA) expression were determined. The effects of celecoxib on PPARγ were assessed in RMC co-transfected with PPARγ and luciferase reporter constructs.

Results

Under resting conditions, RMC expressed COX-1, COX-2 and 12/15-lipoxygenase and mainly generated prostaglandin (PG)E2, thromboxane (TX)B2, 12-hydroxyeicosatetraenoic acid (12-HETE) and 8-epi-PGF. Celecoxib, in addition to reducing PGE2, significantly decreased 8-epi-PGF formation. In the presence of albumin, celecoxib also reduced TXB2 and 12-HETE. Albumin per se inhibited PGE2 as well as renin release. In trans-activation assays, celecoxib acted as a PPARγ agonist whereas albumin inhibited PPARγ as well as 15d-PGJ2-induced PPARγ activation. Finally, celecoxib and albumin potentiated the inhibitory effect of 15d-PGJ2 on α-SMA expression.

Conclusions

These data provide novel molecular mechanisms of celecoxib and their modulation by albumin, that may be relevant to prevent renal dysfunction in conditions of unbalanced effective blood volume.

Keywords: Cyclooxygenase-2, PPARγ, Albumin, Prostaglandins, Renin, 8-Isoprostanes

 

 The authors state that they did not receive funding from the drug manufacturers of the study. However, they state that one author, Jaime L. Masferrer, is an employee of the company.

PII: S0168-8278(04)00433-7

doi:10.1016/j.jhep.2004.09.011

Journal of Hepatology
Volume 42, Issue 1 , Pages 75-81, January 2005